Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 610

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 610
---
 23.6%   | ​ | ​ |
| Loss from operations       | ​ | ​ | ​                              | ​ | -17,305 | ​ | ​ | ​ | ​    | ​ | -14,001 | ​ | ​ | ​ | ​      | ​ | -3,304 | ​ | ​ | ​ | ​       | ​ | 23.6%   | ​ | ​ |
| Interest income            | ​ | ​ | ​                              | ​ |     615 | ​ | ​ | ​ | ​    | ​ |   1,005 | ​ | ​ | ​ | ​      | ​ |   -390 | ​ | ​ | ​ | ​       | ​ | (38.8)% | ​ | ​ |
| Net loss                   | ​ | ​ | ​                              | $ | -16,690 | ​ | ​ | ​ | ​    | $ | -12,996 | ​ | ​ | ​ | ​      | $ | -3,694 | ​ | ​ | ​ | ​       | ​ | 28.4%   | ​ | ​ |

349

TABLE OF CONTENTS

Research and Development Expenses Research and development expenses for the nine months ended September 30, 2024 and 2023 were comprised of the following (in thousands, except percentages):

| ​                                                    
 ​                                                    
 Direct research and development expenses by program: 
 TTI-101:                                             | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 ​                              
 ​                              | ​ 
 ​ |      ​ 
      ​ | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | 2023 
 ​    
 ​    | ​ 
 ​ |      ​ 
      ​ | ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | Change 
 Amount 
 ​      
 ​      | ​ 
 ​ |      ​ 
      ​ | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Percent 
 ​       
 ​       | ​ 
 ​ | ​       
 ​       | ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:-----------------------------------------------------|:--|:--|:-------------------------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:-------|:--|-------: